An update on the clinical relevance of the C-reactive protein was published in the second edition of 2023 in the medical magazine Forum Sanitas. Dr. Wolfgang Ries and Dr. Fabrizio Esposito report from the practice of therapies for acute, necrotic pancreatitis and severe myocardial infarction.
The article summarizes the key findings as follows:
- C-reactive protein can act as a mediator of tissue damage.
- High CRP concentrations still mark viable cells for phagocytosis.
- CRP that is already bound to tissue structures can no longer be removed.
- CRP causes cells in the "risk area" of a heart attack wound to be eliminated.
- Some of the STEMI patients showed no infarct scars after CRP apheresis.
- The CRP concentration correlates significantly with the infarct size.
- From a CRP peak value of 22 mg/l, the STEMI patient benefits from CRP apheresis.
- In acute necrotizing pancreatitis, the level of CRP levels correlates with the prognosis and after initial treatments, CRP apheresis represents a promising therapeutic option.
- Both in acute myocardial infarction and in COVID-19, an early reduction in plasma CRP has a positive effect on the course of the disease.
You can find the entire article here on pages 24-26.